Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta-Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension.
Raj DesaiHaesuk ParkJoshua D BrownRajesh MohandasCarl J PepineSteven M SmithPublished in: Hypertension (Dallas, Tex. : 1979) (2022)
Long-term clinical trials powered to assess major adverse cardiovascular events are necessary to understand the risk-benefit trade-off of AA as fourth-line therapy for RH.